Savara has been granted a patent for a method to treat pulmonary NTM infections resistant to antibiotics. The method involves administering GM-CSF via pulmonary administration to the subject for at least 6 months until sputum samples show no NTM presence. GlobalData’s report on Savara gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Savara, Nebulizers and atomisers was a key innovation area identified from patents. Savara's grant share as of April 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of pulmonary ntm infection with gm-csf
A recently granted patent (Publication Number: US11938169B2) outlines a method for treating pulmonary non-tuberculous mycobacterium (NTM) infections in subjects refractory to antibiotic treatment. The method involves administering granulocyte-macrophage colony stimulating factor (GM-CSF) via pulmonary administration at a dosage ranging from 200 µg to 400 µg once or twice daily. The treatment continues weekly or every alternate week for a minimum of 6 months until a sputum sample from the subject shows an absence of NTM, effectively treating the subject. The patent specifies the NTM strains that can be targeted, including Mycobacterium kansasii, Mycobacterium simiae, and Mycobacterium avium complex (MAC), among others.
Furthermore, the patent details the administration methods for GM-CSF, which can be delivered intratracheally, intrabronchially, or intraalveolarly. The subject can receive the treatment in the form of a nebulized solution, a suspension, a nebulized aerosol, or an inhaled powder. The patent also mentions the possibility of administering GM-CSF concomitantly with antibiotics and specifies the GM-CSF variants that can be used, such as Molgramostim, Regramostim, or Sargramostim. The method is particularly targeted towards subjects with NTM infections like Mycobacterium abscessus, Mycobacterium intracellulare, or a combination of both, who have shown resistance to traditional antibiotic treatments.
To know more about GlobalData’s detailed insights on Savara, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
